Novartis | NVS - Current Assets


Novartis reported $28.2B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Bausch Health Companies USD 6.16B 92M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Canopy Growth CAD 445.82M 142.46M Sep/2025
Corcept Therapeutics USD 541.13M 98.02M Sep/2025
Drreddys Laboratories INR 3.31B 164.26M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
J&J USD 55.62B 1.01B Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pacira USD 562.75M 182.86M Sep/2025
Perrigo USD 2.88B 264.2M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Phibro Animal Health USD 862.18M 26.39M Dec/2025
Prestige Brands USD 433.43M 63.98M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Supernus Pharmaceuticals USD 593.89M 144.98M Sep/2025
Zoetis USD 6.77B 185M Dec/2025